MEDULLARY THYROID CANCER
Clinical trials for MEDULLARY THYROID CANCER explained in plain language.
Never miss a new study
Get alerted when new MEDULLARY THYROID CANCER trials appear
Sign up with your email to follow new studies for MEDULLARY THYROID CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Targeted pill tested for Hard-to-Treat cancers driven by RET gene
Disease control OngoingThis study is testing an oral medication called selpercatinib (LOXO-292) for people with advanced solid tumors that have a specific genetic change in the RET gene. The goal is to find a safe dose and see if the drug can shrink these difficult-to-treat cancers. It is for patients …
Matched conditions: MEDULLARY THYROID CANCER
Phase: PHASE1, PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New pill tested in kids with Hard-to-Treat cancers
Disease control OngoingThis study is testing a pill called LOXO-292 in children and teenagers with advanced solid or brain tumors that have a specific genetic change called a RET alteration. The goal is to find a safe and effective dose and to see if the medicine can shrink these difficult-to-treat tum…
Matched conditions: MEDULLARY THYROID CANCER
Phase: PHASE1, PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Cancer trial seeks same results with fewer side effects
Disease control OngoingThis study aims to see if a lower daily dose (60 mg) of the cancer drug cabozantinib works as well as the standard higher dose (140 mg) for people with advanced medullary thyroid cancer that is getting worse. Researchers want to find out if the lower dose can control the cancer f…
Matched conditions: MEDULLARY THYROID CANCER
Phase: PHASE4 • Sponsor: Exelixis • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New hope for advanced thyroid cancer patients in major drug trial
Disease control OngoingThis study is comparing a new targeted drug called selpercatinib against standard treatments for advanced thyroid cancer that has a specific genetic change (RET mutation) and is getting worse. It involves adults (and some teens) whose cancer cannot be removed by surgery or has sp…
Matched conditions: MEDULLARY THYROID CANCER
Phase: PHASE3 • Sponsor: Loxo Oncology, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:27 UTC